Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepSTAR: TACE vs TACE + SABR in BCLC B Hepatocellular Carcinoma
NCT02958163Phase 2Terminated
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin in hepatocellular carcinoma (HCC). Primary endpoint: Objective Response Rate at 6 months. Started Feb 2017; status: terminated.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02958163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958163.